66 related articles for article (PubMed ID: 30414955)
1. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
Gergis U; Frenet EM; Shore T; Mayer S; Phillips A; Hsu JM; Roboz G; Ritchie E; Scandura J; Lee S; Desai P; Samuel M; Ball J; Blanco A; Romeo C; Albano MS; Dobrila L; Scaradavou A; van Besien K
Biol Blood Marrow Transplant; 2019 Mar; 25(3):466-473. PubMed ID: 30414955
[TBL] [Abstract][Full Text] [Related]
2. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.
Ahmadvand M; Barough MS; Barkhordar M; Faridfar A; Ghaderi A; Jalaeikhoo H; Rajaienejad M; Majidzadeh K; Ghavamzadeh A; Sarrami-Forooshani R
BMC Cancer; 2023 Nov; 23(1):1090. PubMed ID: 37950209
[TBL] [Abstract][Full Text] [Related]
3. Non-Inherited Maternal Antigens Identify Acceptable HLA Mismatches: A New Policy for the Hellenic Cord Blood Bank.
Panagouli E; Dinou A; Mallis P; Michalopoulos E; Papassavas A; Spyropoulou-Vlachou M; Meletis J; Angelopoulou M; Konstantopoulos K; Vassilakopoulos T; Stavropoulos-Giokas C
Bioengineering (Basel); 2018 Sep; 5(4):. PubMed ID: 30248919
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
Linder K; Lulla P
Hum Vaccin Immunother; 2021 Aug; 17(8):2602-2616. PubMed ID: 33941042
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Spillane DR; Assouline S
Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
[TBL] [Abstract][Full Text] [Related]
6. Successful Bone Marrow Transplantation in a Patient with Acute Myeloid Leukemia Developed from Severe Congenital Neutropenia Using Modified Chemotherapy and Conditioning Regimen for Leukemia.
Matsumura R; Mochizuki S; Morishita Y; Hayakawa H; Karakawa S; Kawaguchi H; Okada S; Hyakuna N; Kobayashi M
Hematol Rep; 2024 Feb; 16(1):98-105. PubMed ID: 38534880
[TBL] [Abstract][Full Text] [Related]
7. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
Przespolewski AC; Griffiths EA
Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Smits EL; Lee C; Hardwick N; Brooks S; Van Tendeloo VF; Orchard K; Guinn BA
Cancer Immunol Immunother; 2011 Jun; 60(6):757-69. PubMed ID: 21519825
[TBL] [Abstract][Full Text] [Related]
9. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy.
Molina JC; Li Y; Otto WR; Miller TP; Getz KD; Mccoubrey C; Ramos M; Krause E; Cao L; Gramatges MM; Rabin K; Scheurer M; Elgarten CW; Myers RM; Seif AE; Fisher BT; Shah NN; Aplenc R
Pediatr Blood Cancer; 2023 Jan; 70(1):e30062. PubMed ID: 36370087
[TBL] [Abstract][Full Text] [Related]
10. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia.
Sasaki K; Ravandi F; DiNardo C; Welch MA; Kadia T; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):905-910. PubMed ID: 37730483
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou AM; Guenther K; Andersson BS; Mendrzyk R; Alpert A; Wagner C; Nowak A; Aslan K; Satelli A; Richter F; Kuttruff-Coqui S; Schoor O; Fritsche J; Coughlin Z; Mohamed AS; Sieger K; Norris B; Ort R; Beck J; Vo HH; Hoffgaard F; Ruh M; Backert L; Wistuba II; Fuhrmann D; Ibrahim NK; Morris VK; Kee BK; Halperin DM; Nogueras-Gonzalez GM; Kebriaei P; Shpall EJ; Vining D; Hwu P; Singh H; Reinhardt C; Britten CM; Hilf N; Weinschenk T; Maurer D; Walter S
Cancer Immunol Res; 2023 Jul; 11(7):925-945. PubMed ID: 37172100
[TBL] [Abstract][Full Text] [Related]
12. AMPK activation induces immunogenic cell death in AML.
Mondesir J; Ghisi M; Poillet L; Bossong RA; Kepp O; Kroemer G; Sarry JE; Tamburini J; Lane AA
Blood Adv; 2023 Dec; 7(24):7585-7596. PubMed ID: 37903311
[TBL] [Abstract][Full Text] [Related]
13. Relapsed or primary refractory AML: moving past MEC and FLAG-ida.
Koenig K; Mims A
Curr Opin Hematol; 2020 Mar; 27(2):108-114. PubMed ID: 31904664
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.
Ambinder AJ; Norsworthy K; Hernandez D; Palau L; Paun B; Duffield A; Chandraratna R; Sanders M; Varadhan R; Jones RJ; Douglas Smith B; Ghiaur G
Front Oncol; 2020; 10():587062. PubMed ID: 33194741
[TBL] [Abstract][Full Text] [Related]
15. Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.
Ramos NR; Mo CC; Karp JE; Hourigan CS
J Clin Med; 2015 Apr; 4(4):665-95. PubMed ID: 25932335
[TBL] [Abstract][Full Text] [Related]
16. [The guidelines for diagnosis and treatment of relapse /refractory acute myelogenous leukemia in China (2023)].
Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):713-716. PubMed ID: 38049313
[No Abstract] [Full Text] [Related]
17. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.
Pollyea DA; Stevens BM; Jones CL; Winters A; Pei S; Minhajuddin M; D'Alessandro A; Culp-Hill R; Riemondy KA; Gillen AE; Hesselberth JR; Abbott D; Schatz D; Gutman JA; Purev E; Smith C; Jordan CT
Nat Med; 2018 Dec; 24(12):1859-1866. PubMed ID: 30420752
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.
Chaekal OK; Scaradavou A; Masson Frenet E; Albano MS; Cushing M; Desai P; Dobrila L; Gergis U; Guarneri D; Hsu JM; Lee S; Mayer SA; Phillips AA; Orfali N; Ritchie EK; Roboz GJ; Romeo C; Samuel MS; Shore T; van Besien K
Blood Adv; 2020 Oct; 4(20):5146-5156. PubMed ID: 33091124
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Kim HT; Ahn KW; Hu ZH; Davids MS; Volpe VO; Antin JH; Sorror ML; Shadman M; Press O; Pidala J; Hogan W; Negrin R; Devine S; Uberti J; Agura E; Nash R; Mehta J; McGuirk J; Forman S; Langston A; Giralt SA; Perales MA; Battiwalla M; Hale GA; Gale RP; Marks DI; Hamadani M; Ganguly S; Bacher U; Lazarus H; Reshef R; Hildebrandt GC; Inamoto Y; Cahn JY; Solh M; Kharfan-Dabaja MA; Ghosh N; Saad A; Aljurf M; Schouten HC; Hill BT; Pawarode A; Kindwall-Keller T; Saba N; Copelan EA; Nathan S; Beitinjaneh A; Savani BN; Cerny J; Grunwald MR; Yared J; Wirk BM; Nishihori T; Chhabra S; Olsson RF; Bashey A; Gergis U; Popat U; Sobecks R; Alyea E; Saber W; Brown JR
Clin Cancer Res; 2019 Aug; 25(16):5143-5155. PubMed ID: 31253630
[TBL] [Abstract][Full Text] [Related]
20. Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.
Ai H; Chao NJ; Rizzieri DA; Huang X; Spitzer TR; Wang J; Guo M; Keating A; Krakow EF; Blaise D; Ma J; Wu D; Reagan J; Gergis U; Duarte RF; Chaudhary PM; Hu K; Yu C; Sun Q; Fuchs E; Cai B; Huang Y; Qiao J; Gottlieb D; Schultz KR; Liu M; Chen X; Chen W; Wang J; Zhang X; Li J; Huang H; Sun Z; Li F; Yang L; Zhang L; Li L; Liu K; Jin J; Liu Q; Liu D; Gao C; Fan C; Wei L; Zhang X; Hu L; Zhang W; Tian Y; Han W; Zhu J; Xiao Z; Zhou D; Zhang B; Jia Y; Zhang Y; Wu X; Shen X; Lu X; Zhan X; Sun X; Xiao Y; Wang J; Shi X; Zheng B; Chen J; Ding B; Wang Z; Zhou F; Zhang M; Zhang Y; Sun J; Xia B; Chen B; Ma L
Heliyon; 2023 Apr; 9(4):e14924. PubMed ID: 37089296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
